A previous study of adjuvant trastuzumab in HER2 positive breast cancer has shown that trastuzumab benefit limited only to patients with high TILs10 and therefore, we wanted to address whether CD8 CT phenotype could predict benefit from trastuzumab in metastatic setting. The gene discussed is ERBB2; the disease is breast cancer.